Skip to content

In the BioHarmony Drug Report Database

Duloxetine

Cymbalta, Drizalma Sprinkle, Duloxetine Lilly, Yentreve (duloxetine) is a small molecule pharmaceutical. Duloxetine was first approved as Cymbalta on 2004-08-03. It is used to treat anxiety disorders, diabetic neuropathies, major depressive disorder, and musculoskeletal pain in the USA. It has been approved in Europe to treat anxiety disorders, diabetes mellitus, diabetic neuropathies, major depressive disorder, and neuralgia amongst others. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 6, and Na(+):neurotransmitter symporter (Snf family). Cymbalta's patent is valid until 2037-04-13 (FDA).
Trade Name Cymbalta, Duloxetine Lilly, Yentreve
Common Name Duloxetine
Indication anxiety disorders, diabetes mellitus, diabetic neuropathies, major depressive disorder, musculoskeletal pain, neuralgia, stress urinary incontinence
Drug Class Antidepressants (fluoxetine type)
Duloxetine
Get full access now